Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) has issued an announcement.
IRLAB Therapeutics AB announced its participation in the Aktiedagarna event in Stockholm, where CEO Kristina Torfgård will present the company’s developments on June 10. This engagement highlights IRLAB’s active role in the industry, potentially enhancing its visibility and stakeholder engagement as it progresses its Parkinson’s disease treatment pipeline.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a Swedish company focused on discovering and developing innovative treatments for Parkinson’s disease. Originating from Nobel Laureate Prof Arvid Carlsson’s research, the company is advancing a portfolio of treatments targeting various stages of Parkinson’s disease, including Mesdopetam, Pirepemat, and IRL757, along with preclinical programs IRL942 and IRL1117. Their research is driven by a proprietary systems biology-based platform, and they are listed on Nasdaq Stockholm.
Average Trading Volume: 85,213
Current Market Cap: SEK368.3M
Learn more about IRLAB.A stock on TipRanks’ Stock Analysis page.